

GLOBAL MED TECHNOLOGIES INC
Form 3
April 01, 2010

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â HAEMONETICS CORP		(Month/Day/Year)	GLOBAL MED TECHNOLOGIES INC [GLOB]	
(Last)	(First)	(Middle)	03/25/2010	
400 WOOD ROAD,Â		4. Relationship of Reporting Person(s) to Issuer		5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)		(Check all applicable)		6. Individual or Joint/Group Filing(Check Applicable Line)
BRAINTREE,Â MAÂ 02184		<input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below)		<input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person
(City)	(State)	(Zip)		

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	31,428,730	I	See Footnote ⁽¹⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable Expiration Date	Title Amount or Number of			

				Shares		(I) (Instr. 5)	
Series A Convertible Preferred Stock	Â (2)(3)	Â (2)(3)	Common Stock	5,500,000	\$ 0.72 (4)	I	See Footnote (1)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
HAEMONETICS CORP 400 WOOD ROAD BRAintree, MA 02184	Â	Â X	Â	Â
Atlas Acquisition Corp. C/O HAEMONETICS CORPORATION 400 WOOD ROAD BRAintree, MA 02184	Â	Â X	Â	Â

Signatures

HAEMONETICS CORPORATION /s/ Christopher J. Lindop, its Chief Financial Officer 04/01/2010

__Signature of Reporting Person

Date

ATLAS ACQUISITION CORP. /s/ Christopher J. Lindop, its President 04/01/2010

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The reported securities are owned indirectly by Haemonetics Corporation ("Haemonetics") and directly by Atlas Acquisition Corp. ("Atlas"), a wholly-owned subsidiary of Haemonetics. The reported securities were acquired by Atlas in connection with the cash tender offer to purchase all outstanding shares of convertible preferred stock and Common Stock of the Issuer commenced by Atlas on February 19, 2010.

(2) Subject to the "blocker" provisions described in footnote 3, the convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.

(3) The convertible preferred stock is subject to "blocker" provisions prohibiting the holder from converting the preferred stock to the extent that such conversion would result in the holder being deemed the beneficial owner of more than 9.99% of the issued and outstanding shares of the Common Stock.

(4) Subject to the "blocker" provisions described in footnote 3, the shares of convertible preferred stock are convertible at a rate of 1-to-1,388.89 into the number of shares of Common Stock shown in column 3.

Â

Remarks:

This report is filed jointly by Haemonetics Corporation and Atlas Acquisition Corp.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.